News stories about Impax Laboratories (NASDAQ:IPXL) have been trending positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 47.5961447553646 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Impax Laboratories, Inc. – IPXL – PR Newswire (press release) (prnewswire.com)
- ETFs with exposure to Impax Laboratories, Inc. : December 15, 2017 (finance.yahoo.com)
- Cantor Fitzgerald Analysts Give Impax Laboratories (IPXL) a $35.00 Price Target (americanbankingnews.com)
- Impax Laboratories (IPXL) Announces Tentative FDA Approval of Generic Coreg CR Extended-Release Capsules – StreetInsider.com (streetinsider.com)
Shares of Impax Laboratories (IPXL) opened at $18.65 on Friday. Impax Laboratories has a 52-week low of $7.75 and a 52-week high of $25.70. The firm has a market cap of $1,319.22, a P/E ratio of 26.18, a PEG ratio of 1.12 and a beta of 0.94. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32.
Several research firms have issued reports on IPXL. Cantor Fitzgerald reissued a “buy” rating and issued a $25.00 price objective on shares of Impax Laboratories in a research report on Monday, September 25th. BTIG Research reissued a “buy” rating and issued a $27.00 price objective (up from $20.00) on shares of Impax Laboratories in a research report on Saturday, September 23rd. Goldman Sachs Group began coverage on shares of Impax Laboratories in a research report on Thursday, September 28th. They issued a “neutral” rating and a $20.00 price objective for the company. Zacks Investment Research cut shares of Impax Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, October 20th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $23.00 price target on shares of Impax Laboratories in a research report on Tuesday, September 19th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company’s stock. Impax Laboratories has an average rating of “Hold” and an average target price of $19.47.
TRADEMARK VIOLATION WARNING: “Impax Laboratories (IPXL) Earning Favorable News Coverage, Report Finds” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2017/12/17/impax-laboratories-ipxl-earning-favorable-news-coverage-report-finds.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.